These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1350353)

  • 1. Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression.
    Amsterdam JD
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 May; 16(3):271-80. PubMed ID: 1350353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gepirone as a 5-HT1A agonist in the treatment of major depression.
    Rausch JL; Ruegg R; Moeller FG
    Psychopharmacol Bull; 1990; 26(2):169-71. PubMed ID: 1978370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gepirone in the treatment of major depression.
    Jenkins SW; Robinson DS; Fabre LF; Andary JJ; Messina ME; Reich LA
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):77S-85S. PubMed ID: 1973942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.
    Robinson DS; Rickels K; Feighner J; Fabre LF; Gammans RE; Shrotriya RC; Alms DR; Andary JJ; Messina ME
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):67S-76S. PubMed ID: 2198303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients.
    Rausch JL; Stahl SM; Hauger RL
    Biol Psychiatry; 1990 Jul; 28(1):73-8. PubMed ID: 1973905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement.
    McGrath PJ; Stewart JW; Quitkin FM; Wager S; Jenkins SW; Archibald DG; Stringfellow JC; Robinson DS
    J Clin Psychopharmacol; 1994 Oct; 14(5):347-52. PubMed ID: 7806692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties.
    Kaur Gill A; Bansal Y; Bhandari R; Kaur S; Kaur J; Singh R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Jul; 55(7):423-437. PubMed ID: 31347611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.
    Fabre LF; Brown CS; Smith LC; Derogatis LR
    J Sex Med; 2011 May; 8(5):1411-9. PubMed ID: 21324094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD
    Psychopharmacol Bull; 1996; 32(4):659-65. PubMed ID: 8993088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gepirone and the treatment of panic disorder: an open study.
    Pecknold JC; Luthe L; Scott-Fleury MH; Jenkins S
    J Clin Psychopharmacol; 1993 Apr; 13(2):145-9. PubMed ID: 8096526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men.
    Fabre LF; Clayton AH; Smith LC; Goldstein I; Derogatis LR
    J Sex Med; 2012 Mar; 9(3):821-9. PubMed ID: 22240272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic anxiolytics and treatment of depression.
    Robinson DS; Alms DR; Shrotriya RC; Messina M; Wickramaratne P
    Psychopathology; 1989; 22 Suppl 1():27-36. PubMed ID: 2657837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis.
    Fabre LF; Smith LC; DeRogatis LR
    J Sex Med; 2011 Sep; 8(9):2569-81. PubMed ID: 21707926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.
    Robinson DS; Sitsen JM; Gibertini M
    Clin Ther; 2003 Jun; 25(6):1618-33. PubMed ID: 12860488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
    Bielski RJ; Cunningham L; Horrigan JP; Londborg PD; Smith WT; Weiss K
    J Clin Psychiatry; 2008 Apr; 69(4):571-7. PubMed ID: 18373383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepirone in anxiety: a pilot study.
    Csanalosi I; Schweizer E; Case WG; Rickels K
    J Clin Psychopharmacol; 1987 Feb; 7(1):31-3. PubMed ID: 2880873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications.
    Casacalenda N; Boulenger JP
    Can J Psychiatry; 1998 Sep; 43(7):722-30. PubMed ID: 9773222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.